Aggressive Behavior and Elevated Lactate Dehydrogenase at Baseline Confer Inferior Prognosis in Patients With Primary Cutaneous Lymphoma

Liu, Wei Ping; Song, Yinggai; Zheng, Wen; Wang, Xiao Pei; Ding, Ning; Zhu, Jun

doi:10.1016/j.clml.2013.04.011

Cited by 4 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once a diagnosis of CTCL is established, additional diagnostic testing is conducted in accordance with current National Comprehensive Cancer Network guidelines for the workup and staging of cutaneous lymphomas (31). These diagnostic tests include PET/CT scans and laboratory studies, such as complete blood count, differential, comprehensive metabolic panel, lactic dehydrogenase, serum protein electrophoresis/quantitative immunoglobulins, molecular testing with cytogenetics, fluorescence in situ hybridization, flow cytometry, and viral studies (32), as clinically indicated. A bone marrow biopsy is also performed in select cases of CTCL (33).…”

Section: Discussionmentioning

confidence: 99%

Utility of flow cytometry and gene rearrangement analysis in tissue and blood of patients with suspected cutaneous T‑cell lymphoma

Gibbs

Kim

et al. 2020

Oncol Rep

View full text Add to dashboard Cite

Cutaneous T-cell lymphoma (CTCL) is difficult to diagnose at an early stage. Current diagnostic tools include clinical examination, histomorphologic analysis, immunohistochemistry, flow cytometry of peripheral blood and/or lesional tissue, and evaluation of T-cell receptor (TCR) clonality by gene rearrangement analysis (TCRGR). Advances in genomic sequencing, including high-throughput sequencing (HTS), can be used to identify specific clones of rearranged TCR genes. Even with all of these tools, CTCL can take as long as a decade to definitively diagnose, potentially delaying treatment options and causing patient anxiety. This study aimed to evaluate the performance of the various ancillary testing modalities used to diagnose early-stage CTCL. In a subset of patients the performance of HTS was compared to flow cytometry and conventional TCRGR analysis via polymerase chain reaction (PCR). Fifty-five patients, with a total of 68 skin biopsies and peripheral blood draws, were evaluated using flow cytometry, PCR-TCRGR, and HTS-TCRGR to determine the sensitivity and specificity of each ancillary test. In tissue biopsies, flow cytometry (64%), PCR (71%) and HTS (69%) shared similar sensitivities; flow cytometry had the highest specificity (93%), followed by HTS (86%) and PCR (76.9%). However, flow cytometry and PCR had insufficient DNA quantities in 29 and 15% of the specimens, respectively. Peripheral blood testing was less sensitive than tissue testing (flow cytometry 14%, PCR 41%, HTS 33%); in peripheral blood, HTS was the most specific test (flow cytometry, 70%; PCR, 62.5%; and HTS, 100%). HTS is a highly specific molecular test for identifying CTCL in peripheral blood and skin biopsy specimens; however, our findings suggest a need for a continued search for more sensitive tests for early-stage CTCL.

show abstract

Section: Discussionmentioning

confidence: 99%

Utility of flow cytometry and gene rearrangement analysis in tissue and blood of patients with suspected cutaneous T‑cell lymphoma

Gibbs

Kim

et al. 2020

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…HK2 is also required to promote the growth of DLBCL cells under hypoxia [ 24 ] ( Table 1 ). Increased levels of serum lactate dehydrogenase (LDH) in primary cutaneous lymphoma (PCL) have been associated with independent risk factors for progression-free survival (PFS) rate and overall survival (OS) rate [ 25 ] ( Table 1 ). The LDH-5 is upregulated in non-Hodgkin lymphoma (NHL), which is directly related to clinical stage, extra-nodal site involvement, and performance status of patients with NHL [ 26 ] ( Table 1 ).…”

Section: Metabolic Alterations In Lymphomamentioning

confidence: 99%

Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma

Pang

Xu-Monette

et al. 2023

IJMS

View full text Add to dashboard Cite

Lymphoma is a heterogeneous group of diseases that often require their metabolism program to fulfill the demand of cell proliferation. Features of metabolism in lymphoma cells include high glucose uptake, deregulated expression of enzymes related to glycolysis, dual capacity for glycolytic and oxidative metabolism, elevated glutamine metabolism, and fatty acid synthesis. These aberrant metabolic changes lead to tumorigenesis, disease progression, and resistance to lymphoma chemotherapy. This metabolic reprogramming, including glucose, nucleic acid, fatty acid, and amino acid metabolism, is a dynamic process caused not only by genetic and epigenetic changes, but also by changes in the microenvironment affected by viral infections. Notably, some critical metabolic enzymes and metabolites may play vital roles in lymphomagenesis and progression. Recent studies have uncovered that metabolic pathways might have clinical impacts on the diagnosis, characterization, and treatment of lymphoma subtypes. However, determining the clinical relevance of biomarkers and therapeutic targets related to lymphoma metabolism is still challenging. In this review, we systematically summarize current studies on metabolism reprogramming in lymphoma, and we mainly focus on disorders of glucose, amino acids, and lipid metabolisms, as well as dysregulation of molecules in metabolic pathways, oncometabolites, and potential metabolic biomarkers. We then discuss strategies directly or indirectly for those potential therapeutic targets. Finally, we prospect the future directions of lymphoma treatment on metabolic reprogramming.

show abstract

“…To date, no molecular, histologic, or clinical criteria are available that can consistently distinguish PCBCL from sBCL with cutaneous involvement. Discerning histologic or molecular features combined with easily attainable prognostic biomarkers would be instrumental in guiding treatment decisions and is an ongoing objective of the International Society of Cutaneous Lymphoma (ISCL) [8][9][10]. Until these markers can be firmly established, it remains imperative that sBCL is excluded in all patients presenting with CBCL.…”

Section: Introductionmentioning

confidence: 99%

Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University

et al. 2015

View full text Add to dashboard Cite

Background. The increasing incidence of primary cutaneous B-cell lymphomas (PCBCLs) presents new challenges for clinicians. Despite advances in the clinical and pathologic characterization of PCBCL, the significance of the current staging approach as a risk profiling tool and the effect of various treatments on outcome remain unclear. Materials and Methods. We retrospectively reviewed patients who presented with a diagnosis of PCBCL seen at The Ohio State University between 1998 and 2012. We reviewed the initial presentation and treatment modality.We then assessed whether the treatment modality (conservative skin-directed vs. definitive radiation with or without systemic therapy), stage (T1 or $T2), or histologic subtype (primary cutaneous follicle center lymphoma [PCFCL] vs. primary cutaneous marginal zone B-cell lymphoma [PCMZL]) affected the riskof recurrence. Results. We identified 67 patients referred with an initial diagnosis of PCBCL. After imaging, 12 did not meet the criteria

show abstract

Aggressive Behavior and Elevated Lactate Dehydrogenase at Baseline Confer Inferior Prognosis in Patients With Primary Cutaneous Lymphoma

Cited by 4 publications

References 24 publications

Utility of flow cytometry and gene rearrangement analysis in tissue and blood of patients with suspected cutaneous T‑cell lymphoma

Utility of flow cytometry and gene rearrangement analysis in tissue and blood of patients with suspected cutaneous T‑cell lymphoma

Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma

Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University

Contact Info

Product

Resources

About